SCHEMBL9944189

SCHEMBL9944189

CCOc1c(Br)cc(C(=O)Nc2ccc(C(C)=O)c(C)c2)cc1Br

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
SMN1; SMN2 Q16637 8/20 0.52
NPC1 O15118 5/20 0.52
RAB9A P51151 4/20 0.52
TP53 P04637 5/20 0.51
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.47
LMNA P02545 1/20 0.47
P4HTM Q9NXG6 1/20 0.46
KDM4E B2RXH2 3/20 0.46
POLB P06746 1/20 0.46
CYP1A2 P05177 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944208 0.95 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL1458178 0.92 MAPT (0.56) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944191 0.88 MEN1 (0.62) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944195 0.87 MAPT (0.62) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944150 0.87 MAPT (0.54) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944169 0.86 MEN1 (0.57) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944181 0.85 SMN1; SMN2 (0.62) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944241 0.85 MAPT (0.51) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944207 0.85 KMT2A (0.53) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL9944186 0.84 RAB9A (0.53) MAPTKMT2AMEN1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885KMT2A 1418/4885MEN1 4809/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885KMT2A 1418/4885MEN1 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.